A novel recombinant anti-EGFR peptide vaccine capable of active immunization and reduction of tumor volume in mice model.
Mohamad Javad Rasaee
MetadataShow full item record
Over-expression of the Epidermal Growth Factor Receptor (EGFR) has been reported in a number of human malignancies. High levels of expression of this receptor have been associated with poor survival in many such patients. Active immunizations that elicit antibodies of the desired type could be an appealing alternative for conventional passive immunization. In this regard, we decide to construct a novel recombinant peptide vaccine capable of prophylactic and therapeutic effects. A novel fusion recombinant peptide base vaccine consisting of L2 domain of murine ECD-EGFR and EGFR mimotope (EM-L2) was constructed and its prophylactic and therapeutic effects on the Lewis lung carcinoma mice (C57/BL6) model were evaluated. Constructed recombinant peptide vaccine is capable of reacting with anti EGFR antibodies. Immunization of mice with EM-L2 peptide resulted in antibody production against EM-L2. The constructed recombinant peptide vaccine reduced tumor growth and increased the survival rate. Designing effective peptide vaccines could be deemed as an encouraging strategy in contemporary cancer immunotherapy. Investigating the efficacy of these cancer immunotherapy approaches may open an exciting possibility on the hyper immunization, leading to more promising results of tumor regression and proliferation.